ENDP, PRAN, TAYC, CRME, PJA, LBTYA Are Seasonally Ripe To Go Up In the Next Five Weeks
Dec 20, 2012 (M2 PRESSWIRE via COMTEX) --
BUYINS.NET / www.squeezetrigger.com is monitoring the Seasonality of Endo Pharmaceuticals Holdings Inc (NASDAQ:ENDP), Prana Biotechnology Ltd (NASDAQ:PRAN), Taylor Capital Group Inc (NASDAQ:TAYC), CARDIOME PHARMA CORP (NASDAQ:CRME), Preferredplus Trust Series Qws-2 (NYSE:PJA), Liberty Global Inc (NASDAQ:LBTYA) and each have a high seasonal probability to go Up in the next weeks. By identifying stocks that are poised to go up or down based on seasonal tendencies, traders can increase their odds of making money. SqueezeTrigger.com is able to analyze over 20 years of data in less than 1 second for any stock in the market and determine if the stock has a long or short seasonal bias, how many trading days the move is expected to last, the probability of that move and the percentage move the stock is expected to make based on the seasonal bias. The technology used to generate these predictions is available for a low monthly fee at:
The following stocks are expected to go Up:
Symbol Company Expected Return Odds By The Following Date
ENDP Endo Pharmaceuticals Holdings Inc 6.88% 75.00% (9 of 12) Tuesday, January 1st 2013
PRAN Prana Biotechnology Ltd 4.76% 90.00% (9 of 10) Friday, January 4th 2013
TAYC Taylor Capital Group Inc 1.94% 90.00% (9 of 10) Friday, December 21st 2012
CRME CARDIOME PHARMA CORP 10.97% 87.50% (7 of 8) Wednesday, January 9th 2013
PJA Preferredplus Trust Series Qws-2 8.91% 90.91% (10 of 11) Tuesday, January 29th 2013
LBTYA Liberty Global Inc 2.56% 87.50% (7 of 8) Thursday, December 27th 2012
Endo Pharmaceuticals Holdings Inc (NASDAQ:ENDP) - Endo Pharmaceuticals Holdings Inc., through its subsidiary, Endo Pharmaceuticals Inc., engages in the research, development, manufacture, marketing, and sale of branded and generic prescription pharmaceuticals in the United States. Its primary products include Lidoderm, a topical patch product for the relief of the pain associated with post-herpetic neuralgia; Opana and Opana ER, and Percocet for the relief of moderate to severe pain; Voltaren Gel for use in treating pain associated with osteoarthritis; Frova for the acute treatment of migraine headaches in adults; Supprelin LA for treating central precocious puberty (CPP) or the early onset of puberty in children; Vantas for the palliative treatment of advanced prostate cancer; Valstar, a sterile solution for intravesical instillation of valrubicin and BCG-refractory CIS of the bladder; Hydron Implant, a reservoir-based drug delivery system available for parenteral administration; Sanctura for the treatment of overactive bladder (OAB) with symptoms of urge urinary incontinence, urgency, and urinary frequency; and Sanctura XR to treat OAB symptoms. The company also offers generic products, including Endocet and morphine sulfate. In addition, it provides various development stage products, which primarily comprise Aveed for the treatment of male hypogonadism; Fortesta for testosterone replacement therapy in male hypogonadism; Octreotide implant for the treatment of acromegaly; Urocidin for the treatment of non-muscle-invasive bladder cancer that is currently undergoing Phase III clinical testing; and Axomadol in Phase II development for the treatment of moderate to moderately severe chronic pain and diabetic peripheral neuropathic pain. The company has a strategic alliance agreement with Penwest Pharmaceuticals Co.; and a collaboration agreement with Orion Corporation. Endo Pharmaceuticals Holdings was founded in 1997 and is headquartered in Chadds Ford, Pennsylvania..
Prana Biotechnology Ltd (NASDAQ:PRAN) - Prana Biotechnology Limited engages in the research and development of therapeutic drugs for neurological diseases in Australia. The company primarily focuses on the Alzheimers, Parkinsons, and Huntingtons diseases, as well as various age-related degenerative disorders. Its development stage product line includes PBT2, a phase IIb clinical product intended for the Alzheimers disease; and PBT2, a phase IIa clinical product for the Huntingtons disease. The companys products under research comprise PBT434 for the Parkinsons disease, PBT519 for brain cancer, 4E10 for the Alzheimers disease, and PB1568 for the Alzheimers disease imaging. Prana Biotechnology Limited was founded in 1997 and is based in Parkville, Australia..
Taylor Capital Group Inc (NASDAQ:TAYC) - Taylor Capital Group, Inc. operates as the bank holding company for Cole Taylor Bank that provides a range of commercial banking products and services primarily to closely-held commercial customers and their owner operators. Its deposit products include checking, savings, and money market accounts, as well as time deposits, and other deposit and credit services to commercial clients and community-based customers comprising individuals, and small and local businesses. The company s commercial lending activities primarily consist of providing loans for working capital and business expansion or acquisition; owner-occupied commercial real estate financing; revolving lines of credit; and stand-by and commercial letters of credit. It also originates, sells, and services mortgage loans. In addition, the company provides treasury cash management services that include repurchase agreements, interest rate swap, Internet balance reporting, remote deposit capture, positive pay, automated clearing house products, imaged lock-box processing, controlled disbursement, and account reconciliation services to commercial clients; and investment management and brokerage services. Further, it offers asset-based financing, such as revolving lines of credit supported by receivables and inventory; and term loans supported by equipment and real estate. The company s target commercial lending customers comprise businesses in industries, such as manufacturing, wholesale and retail distribution, transportation, construction contracting, and professional services. It operates through nine banking centers in the Chicago area. The company was founded in 1929 and is headquartered in Rosemont, Illinois..
CARDIOME PHARMA CORP (NASDAQ:CRME) - Cardiome Pharma Corp., a life sciences company, engages in developing proprietary drugs to treat or prevent cardiovascular and other diseases. The company offers BRINAVESS, a product approved for marketing in the European Union, Iceland, and Norway for the conversion of recent onset atrial fibrillation to sinus rhythm in adults. It also has clinical programs, which focuses on the treatment of atrial fibrillation, an arrhythmia (or abnormal rhythm) of the upper chambers of the heart. The company has a phase 1 program for GED-aPC, an engineered analog of recombinant human activated Protein C that completed phase I clinical trials for the treatment of infectious disease. In addition, Cardiome Pharma Corp. has pre-clinical projects that focus on cardiac diseases, ion channel conditions, and other indications. It also has a collaboration and license agreement with Merck & Co., Inc. (Merck), for the development and commercialization of vernakalant; and Astellas Pharma US, Inc. to develop, make, and sell intravenous or injectable formulations of vernakalant in North America. The company was formerly known as Nortran Pharmaceuticals Inc. and changed its name to Cardiome Pharma Corp. in June 2001. Cardiome Pharma Corp. was founded in 1986 and is headquartered in Vancouver, Canada..
Preferredplus Trust Series Qws-2 (NYSE:PJA) - Merrill Lynch Depositor Inc. PreferredPLUS 8.00% Trust Certificates Series QWS.
Liberty Global Inc (NASDAQ:LBTYA) - Liberty Global, Inc. provides video, voice, and broadband Internet services primarily in Europe, Japan, and Chile. The company offers various broadband distribution services over its cable television systems, including video, broadband Internet, and telephony. It also provides video services through direct-to-home satellite or multi channel multipoint distribution systems; analog video services consisting of basic programming and expanded basic programming; digital video services comprising basic programming and premium services, as well as pay-per-view programming, including video-on-demand and near-video-on-demand, digital video recorders, and high definition television services; and broadband Internet services. In addition, Liberty Global provides telephony services that include circuit switched telephony services and voice-over-Internet-protocol (VoIP) telephony services, as well as offers mobile telephony services using third party networks. Further, it owns programming networks that provide video programming channels to multi channel distribution systems owned by the company, as well as owned by third parties. As of December 31, 2008, Liberty Global owned and operated networks that passed approximately 34,782,600 homes; and served approximately 15,190,300 video subscribers and 6,727,600 broadband Internet subscribers, as well as 5,230,100 telephony subscribers. The company was founded in 2004 and is based in Englewood, Colorado..
SqueezeTrigger.com has built a massive database that collects, analyzes and publishes multiple proprietary trading strategies that predict price moves in stocks, commodities and currencies. The data has then been integrated into an automated trading platform which can be used to connect to a live online broker and automate your trading of each of the strategies highlighted. It is extremely powerful with lightening fast execution at a very low price. Both the trading software and SqueezeTrigger data feed are available at http://www.squeezetrigger.com
www.squeezetrigger.com monitors trading in all US stocks in real time and maintains massive databases of short sale and naked short sale time and sales data, short squeeze SqueezeTrigger prices, market maker price movements, shareholder data, statistical data on earnings, sector correlation, seasonality, hedge fund trading strategies, comparable valuations. Reports include:
REGULATORY & COMPLIANCE NEWS
Friction Factor -- market maker surveillance system tracking Level II market makers in all stocks to determine Price Friction and compliance with new "Fair Market Making Requirements".
RegSHO Naked Shorts -- tracks EVERY failure to deliver in all US stocks and tracks all Threshold Security Lists daily for which stocks have naked shorts that are not in compliance with Regulation SHO.
INVESTMENTS & TRADING
SqueezeTrigger -- 25 billion cell database tracks EVERY short sale (not just total short interest) in all US stocks and calculates volume weighted price that a short squeeze will begin in each stock.
Earnings Edge -- predicts probability, price move and length of move before and after all US stock earnings reports.
Seasonality -- predicts probability, price move and length of move based on exact time of year for all US stocks.
Group Trader -- tracks sector rotation and stock correlation to its sector and predicts future moves in ALL sectors and industry groups.
Pattern Scan -- automates tracking of every technical pattern and predicts time and size of move in all stocks.
GATS (Global Automated Trading System) -- tracks all known trading strategies and qualifies and quantifies which are working best in real time.
WWW.SQUEEZETRIGGER.COM is a service designed to help bonafide shareholders of publicly traded US companies fight short selling. SqueezeTrigger.com has built a proprietary database that uses Threshold list feeds and short sale time and sale data from NASDAQ, AMEX and NYSE to generate detailed and useful information to combat the short selling problem. For the first time, actual trade by trade data is available to the public that shows the attempted size, actual size, price and average value of short sales in stocks that have been shorted. This information is valuable in determining the precise point at which short sellers go out-of-the-money and start losing on their short trades.
SQUEEZETRIGGER.COM has built a massive database that collects, analyzes and publishes a proprietary SqueezeTrigger for each stock that has been shorted. The SqueezeTrigger database of nearly 2.5 billion short sale transactions goes back to January 1, 2005 and calculates the exact price at which the Total Short Interest is short in each stock. This data was never before available prior to January 1, 2005 because the Self Regulatory Organizations (primary exchanges) guarded it aggressively. After the SEC passed Regulation SHO, exchanges were forced to allow data processors like SqueezeTrigger.com to access the data.
The SqueezeTrigger database collects individual short trade data on over 7,000 NYSE, AMEX and NASDAQ stocks and general short trade data on nearly 8,000 OTCBB and PINKSHEET stocks. Each month the database grows by approximately 50,000,000 short sale transactions and provides investors with the knowledge necessary to time when to buy and sell stocks with outstanding short positions. By tracking the size and price of each montha'a"s short transactions, SQUEEZETRIGGER.COM provides institutions, traders, analysts, journalists and individual investors the exact price point where short sellers start losing money and a short squeeze can begin.
All material herein was prepared by SQUEEZETRIGGER.COM, based upon information believed to be reliable. The information contained herein is not guaranteed by SQUEEZETRIGGER.COM to be accurate, and should not be considered to be all-inclusive. The companies that are discussed in this opinion have not approved the statements made in this opinion.
Occassionally companies pay $995.00 to purchase data for information provided in reports issued by BUYINS.NET, a company affiliated with SQUEEZETRIGGER.COM. The data service can be cancelled at any time. This opinion contains forward-looking statements that involve risks and uncertainties. This material is for informational purposes only and should not be construed as an offer or solicitation of an offer to buy or sell securities. SQUEEZETRIGGER.COM is not a licensed broker, broker dealer, market maker, investment banker, investment advisor, analyst or underwriter. Please consult a broker before purchasing or selling any securities viewed on or mentioned herein. SQUEEZETRIGGER.COM will not advise as to when it decides to sell and does not and will not offer any opinion as to when others should sell; each investor must make that decision based on his or her judgment of the market.
SQUEEZETRIGGER.COM and SQUEEZETRIGGER are intended for use by stock market professionals. As a member, visitor, or user of any kind, you accept full responsibilities for your investment and trading actions. The contents of SQUEEZETRIGGER.COM, including but not limited to all implied or expressed views, opinions, teachings, data, graphs, opinions, or otherwise are not predictions, warranty, or endorsements of any kind. Please seek stock market advice from the proper securities professional, or investment advisor.
By visiting SQUEEZETRIGGER.COM or using any data or services, you agree to assume full responsibility for the decisions or actions that you undertake. Global Automated Trading Systems, LLC, its owner(s), operators, employees, partners, affiliates, advertisers, information providers and any other associated person or entity, shall under no circumstances be held liable to the user and/or any third party for loss or damages of any kind, including but not limited to trading losses, lost trading opportunity, direct, indirect, consequential, special, incidental, or punitive damages. As a user, you agree that any damages collected shall not exceed the amount paid to SQUEEZETRIGGER.COM and/or its owners. As a website user, you agree that any and all legal matters of any kind are to be reviewed and handled in their entirety within the State of California only. By using the services of this website, you are consenting to the terms as outlined, and forfeit all legal jurisdictions in any other State.
Past performance is not a guarantee of future outcomes. Any and all examples are hypothetical and should not be considered a guarantee or endorsement of such trading activity. SQUEEZETRIGGER.COM does not take responsibility for problems of any kind, including but not limited to issues with operations, data accuracy or completeness, contacting issues, technical issues, and timeliness. SQUEEZETRIGGER.COM places great integrity on the data collected and distributed. This information is deemed reliable, but not guaranteed. All information and data is provided "as is" without warranty or guarantee of any kind.
Please seek investment and/or trading advice, council, information or services from a securities professional. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and SQUEEZETRIGGER.COM undertakes no obligation to update such statements.
This release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995.
"Forward-looking statements" describe future expectations, plans, results, or strategies and are generally preceded by words such as "may", "future", "plan" or "planned", "will" or "should", "expected", "anticipates", "draft", "eventually" or "projected". You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a companies' annual report on Form 10-K or 10-KSB and other filings made by such company with the SEC.
Thomas Ronk, CEO
SqueezeTrigger is a registered trademark, Reg. No. 3,120,641
((M2 Communications disclaims all liability for information provided within M2 PressWIRE. Data supplied by named party/parties. Further information on M2 PressWIRE can be obtained at http://www.presswire.net on the world wide web. Inquiries to firstname.lastname@example.org.
[ Back To IBM News 's Homepage ]